Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K963827
    Date Cleared
    1996-10-30

    (36 days)

    Product Code
    Regulation Number
    862.1710
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    for the quantitative determination of free Ts in human serum or plasma (lithium heparin, sodium heparin, or dipotassium EDTA).

    Device Description

    AxSYM Free T2 is a microparticle enzyme immunoassay for the quantitative determination of free Ts in human serum or plasma (lithium heparin, sodium heparin, or dipotassium EDTA). AxSYM Free T3 is calibrated with Abbott calibrators. Abbott controls are assayed for the verification of the accuracy and precision of the Abbott AxSYM System.

    AI/ML Overview

    This 510(k) summary describes a new in-vitro diagnostic device, the Abbott AxSYM Free T3, and compares it to a legally marketed predicate device, the Ciba Corning Automated Chemiluminescence System (ACS) Free T3 Immunoassay. The document focuses on demonstrating substantial equivalence rather than establishing specific performance acceptance criteria for a de novo device.

    Here's an analysis based on your requested criteria:

    1. Table of Acceptance Criteria and Reported Device Performance

    Since this is a substantial equivalence submission, specific numerical acceptance criteria (e.g., minimum sensitivity, specificity, or accuracy targets) are not explicitly stated as they would be for a de novo device. Instead, the "acceptance criterion" is successful correlation with the predicate device.

    Acceptance Criterion (Implicit)Reported Device Performance (AxSYM Free T3 vs. ACS Free T3)
    Strong correlation with predicate deviceCorrelation Coefficient: 0.948
    Acceptable linear relationship with predicate deviceSlope: 1.19
    Low variability around the regression lineStandard Error of Estimate: 0.775
    Acceptable intercept valueY-axis Intercept: -0.96 pg/mL
    Comparable intended useBoth for quantitative determination of free T3
    Comparable analytical range (within clinical utility)AxSYM Free T3 Dynamic Range: 1.1 - 30.0 pg/mL
    ACS Free T3 Dynamic Range: 0.5 - 20.0 pg/mL
    Comparable sample typesAxSYM Free T3: Human serum or plasma (lithium heparin, sodium heparin, or dipotassium EDTA)
    ACS Free T3: Human serum only

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size: 745 specimens
    • Data Provenance: Not explicitly stated. Given the context of a 510(k) summary for a clinical diagnostic, these would typically be human serum/plasma samples, but the country of origin and whether they were retrospective or prospective are not mentioned.

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

    • Not applicable (N/A). For this type of in-vitro diagnostic comparison, ground truth is typically assessed against the performance of a well-established and legally marketed predicate device, not by expert consensus on individual case diagnoses. The "ground truth" for the comparison is the reading from the predicate ACS Free T3 assay.

    4. Adjudication Method for the Test Set

    • Not applicable (N/A). No adjudication method is described, as the comparison is between two quantitative assays, where values are directly measured and correlated rather than requiring expert interpretation and consensus on diagnostic outcomes.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    • No. This is an in-vitro diagnostic device comparison, not a study involving human readers interpreting images or data. Therefore, an MRMC study and effects of AI assistance are not relevant here.

    6. Standalone (Algorithm Only) Performance Study

    • Yes, in the context of an IVD. The "standalone performance" is implicitly demonstrated through the correlation analysis of the AxSYM Free T3 assay when compared to the predicate ACS Free T3 assay using the 745 specimens. The device, in this case, is the assay system itself, and its performance is evaluated directly without human interpretation influencing the quantitative result.

    7. Type of Ground Truth Used

    • Comparative Ground Truth (Predicate Device Measurement). The "ground truth" for this study is the quantitative Free T3 value obtained from the legally marketed and established Ciba Corning Automated Chemiluminescence System (ACS) Free T3 Immunoassay. This is a common approach for 510(k) submissions demonstrating substantial equivalence.

    8. Sample Size for the Training Set

    • Not explicitly stated. The document describes a comparison study, not the development or training of an algorithm in the machine learning sense. For an immunoassay, the "training" involves assay development, reagent optimization, and calibration. The specifics of the samples used for these internal development phases are not typically detailed in a 510(k) summary. The 745 specimens are for the validation/comparison study, not a training set.

    9. How the Ground Truth for the Training Set Was Established

    • Not explicitly stated. As above, the concept of a "training set" with established ground truth as understood in AI/ML is not directly applicable here. For an immunoassay, the "ground truth" for calibration and optimization would be based on reference materials, established laboratory methods, and known concentrations, but the details are not provided.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1